By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy.

OhhMed Medical Ltd., a pioneering medical technology firm specialising in male urology, today announced the initiation of a ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Wider resection of localized high-risk prostate cancer at surgery may come at the cost of sexual function and urinary incontinence. A phase 2 trial tested the merits of neoadjuvant therapy.

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Adding a surgery-specific module to a perioperative telemedicine programme significantly improved functional outcomes after radical prostatectomy, resulting in better urinary continence, a reduced ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...

Low-intensity extracorporeal shock wave therapy (LI-SWT) did not improve erectile dysfunction compared to a sham procedure in radical prostatectomy patients. Fewer than 20% of men in the LI-SWT group ...